| ADR Ontology |
| ADR Term |
Speech sound disorder |
| ADR ID |
BADD_A06838 |
| ADR Hierarchy |
|
| Description |
Disorders of the quality of speech characterized by the substitution, omission, distortion, and addition of phonemes. [MeSH] |
| MedDRA Code |
10077803 |
| MeSH ID |
D001184; D066229; D066229; D066229; D066229
|
|
ADR Severity Grade (FAERS)
|
|
|
ADR Severity Grade (CTCAE)
|
Not Available
|
| Synonym |
| Developmental articulation disorder | Phonological disorder | Speech sound disorder | Articulation Disorders | Articulation Disorder | Speech Articulation Disorders | Articulation Disorder, Speech | Articulation Disorders, Speech | Speech Articulation Disorder | Phonological Impairments | Impairment, Phonological | Impairments, Phonological | Phonological Impairment | Phonology Impairment | Impairment, Phonology | Impairments, Phonology | Phonology Impairments | Disarticulation Disorders | Disarticulation Disorder | Disorder, Disarticulation | Disorders, Disarticulation | Misarticulation | Unintelligible Articulation | Articulation, Unintelligible | Articulations, Unintelligible | Unintelligible Articulations | Articulation Disorders, Developmental | Articulation Disorder, Developmental | Developmental Articulation Disorder | Developmental Articulation Disorders |
|
|
| ADR Related Proteins |
| Protein Name |
UniProt AC |
TTD Target ID |
| Not Available | Not Available | Not Available |
|
| Drugs Leading to the ADR |
| Drug ID | Drug Name | ADR Frequency (FAERS) | ADR Severity Grade (FAERS) | | BADD_D01300 | Lisinopril | 0.000005% | | | BADD_D01599 | Olanzapine | - | - | | BADD_D01617 | Ondansetron | 0.000052% | |
| The 1th Page 1
Total 1 Pages
|
|
